BioNxt's Thin-Film MS Candidate Clears Regulatory Hurdle as Lenders Accept Equity Sweeteners

BioNxt advances MS trial application in Europe, extends debt maturity by a year, but shares remain 65% below 52-week high.

The clinical-stage biotech's shares climbed 8.6% to €0.2280 on Thursday, extending a recent rebound as investors weigh the company's progress toward a European trial application against the substantial ground still lost over the past year. The advance builds on a week of operational milestones, including the completion of the Investigational Medicinal Product Dossier (IMPD) for BNT23001, the company's sublingual cladribine film designed to treat multiple sclerosis.

That dossier, finished last Wednesday, now sits in final regulatory review — the last major step before BioNxt can submit a Clinical Trial Application (CTA) in Europe. The planned study is structured as a randomized, open-label crossover trial in healthy volunteers, designed to demonstrate bioequivalence against the reference product Mavenclad. Success would validate the company's thin-film delivery technology in a clinical setting and potentially offer patients a more convenient alternative to conventional MS treatments.

Debt Maturity Wall Pushed Back a Full Year

The regulatory progress comes on the heels of a financial restructuring announced last Friday that gives the company considerably more runway. BioNxt extended the maturity dates on its unsecured convertible debentures — carrying an 8% interest rate and a total principal of $5.475 million — by one year, pushing repayments into a window between November 12, 2027 and March 14, 2028. Individual tranches include amounts of $1.4 million, $900,000, $865,000, $425,000, and $285,000.

In exchange for the extension, lenders received 16.9 million warrants exercisable at $0.50 per share, valid through August 21, 2027. The arrangement trades near-term repayment pressure for potential future dilution, a calculus that buys management time to hit development milestones without the immediate overhang of looming debt obligations.

The stock's longer-term trajectory, however, tells a more sobering story. Despite Thursday's gains, shares remain 65% below their 52-week high and have shed 46% since the start of the year. The bounce does push the stock back above its 50-day moving average of €0.2082 — a technically constructive signal that traders are watching closely.

Beyond MS: GLP-1 Ambitions and Pipeline Breadth

BioNxt is not resting on its MS program alone. The company is actively exploring additional applications for its thin-film platform in autoimmune and metabolic diseases, with particular attention on the booming GLP-1 receptor agonist market. Reports indicate the sublingual semaglutide program was advanced to its next development stage back in July, positioning the company to potentially address obesity and metabolic disorders with its proprietary delivery technology. Management is currently evaluating commercialization strategies and holding discussions with potential licensing partners.

The broader pipeline update delivered roughly ten days ago also highlighted progress on everolimus and semaglutide programs alongside the portfolio expansion into autoimmune indications. Late July saw the company grant 3.4 million stock options to insiders and advisors at an exercise price of $0.33, a move aimed at locking in key personnel during this critical development phase.

For investors, the near-term catalyst is clear: the impending CTA submission in Europe. Whether that filing can spark a sustained revaluation of the platform — and close the yawning gap to those 52-week highs — remains the central question as BioNxt balances clinical ambition against the realities of its balance sheet.